EKOS System Shows Superiority in Treating Acute Pulmonary Embolism
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy BSX?
Source: Yahoo Finance
- Clinical Trial Results: The HI-PEITHO global randomized trial demonstrated that the EKOS system combined with anticoagulation achieved a primary endpoint event rate of 4.0% in intermediate-risk PE patients, significantly lower than the 10.3% rate for anticoagulation alone, indicating a 61% reduction in events and underscoring the clinical efficacy of the EKOS system.
- Shorter Hospital Stay: Patients treated with the EKOS system experienced no brain bleeding incidents and had a significantly shorter hospital stay compared to those receiving only anticoagulation, which not only reduces healthcare costs but also enhances the overall treatment experience for patients.
- Patient Recruitment and Collaboration: The trial enrolled 544 intermediate-risk PE patients across 59 sites in the U.S. and Europe, showcasing Boston Scientific's collaboration with the PERT Consortium and the University Medical Center Mainz, which advances research in pulmonary embolism treatment.
- Clinical Application Prospects: The findings provide crucial randomized clinical trial data for interventionalists and referring physicians, supporting the consideration of the EKOS system plus anticoagulation as a first-line therapy for acute pulmonary embolism, indicating significant future application potential in the cardiovascular field.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BSX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BSX
Wall Street analysts forecast BSX stock price to rise
22 Analyst Rating
22 Buy
0 Hold
0 Sell
Strong Buy
Current: 69.170
Low
94.00
Averages
108.14
High
132.00
Current: 69.170
Low
94.00
Averages
108.14
High
132.00
About BSX
Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Boston Scientific Schedules Q1 2026 Earnings Call
- Earnings Call Announcement: Boston Scientific Corporation will host a conference call on April 22, 2026, at 8:00 a.m. ET to discuss its financial results for Q1 2026, providing key business highlights and financial data.
- Executive Leadership: The call will be led by Chairman and CEO Mike Mahoney alongside Executive VP and CFO Jon Monson, ensuring that investors receive insights directly from top management regarding the company's financial performance.
- Pre-Call Financial Release: The company plans to issue a news release announcing its Q1 financial results prior to the call, aiming to provide timely information that helps investors understand the company's financial health and future outlook.
- Live Webcast and Replay: The event will be accessible via a live webcast, with a replay available on Boston Scientific's investor website, ensuring that investors who cannot attend in real-time can still access important information.
See More
Mixed Close for US Stocks as Nasdaq Hits 7.75-Month Low Amid Middle East Tensions
- Divergent Market Performance: On Monday, the S&P 500 index fell by 0.39%, while the Nasdaq 100 hit a 7.75-month low, indicating market concerns over the Middle East situation, particularly exacerbated by a sell-off in chip stocks, which negatively impacted investor confidence.
- Declining Bond Yields: The 10-year T-note yield dropped by 8 basis points to 4.34%, reflecting market fears that the ongoing war in the Middle East could lead to fuel shortages, potentially suppressing expectations for Fed rate hikes and highlighting economic growth uncertainties.
- Rising Crude Oil Prices: Crude oil prices surged over 3% to a three-week high due to Iranian attacks on the Strait of Hormuz, indicating severe threats to global energy supply chains, which could lead to soaring prices in the future and impact the global economy.
- Weak Manufacturing Activity: The Dallas Fed manufacturing activity survey fell to -0.2, below the expected 2.0, reflecting signs of economic slowdown that could influence corporate investment decisions and future economic growth.
See More
Boston Scientific Shares Drop 9.02% Amid Trial Update
- Significant Stock Decline: Boston Scientific (BSX) closed at $62.92 on Monday, down 9.03%, reflecting investor concerns over new clinical trial information regarding its heart implant, which has weakened market confidence in the company's future growth prospects.
- Surge in Trading Volume: The trading volume reached 39.9 million shares, approximately 163% above the three-month average of 15.2 million shares, indicating heightened market attention to the company's news, which may lead to increased short-term price volatility.
- Clinical Trial Update: Boston Scientific announced that its CHAMPION-AF trial met all safety and efficacy endpoints for the Watchman FLX heart implant; however, analysts expressed disappointment, suggesting that growth potential may not accelerate as anticipated.
- Investor Sentiment Analysis: While analysts maintained outperform ratings on Boston Scientific, the stock has dropped 38% over the past year, and with a current P/E ratio of just 18 times forward earnings, investors should view the company's future growth potential rationally and avoid overreacting to a single trial outcome.
See More
Boston Scientific Shares Drop 9.03% Amid Trial Update
- Clinical Trial Update: Boston Scientific announced that its CHAMPION-AF trial for the Watchman heart implant met all safety and efficacy endpoints, yet analysts expressed disappointment, suggesting that growth may not accelerate as anticipated, which could impact investor sentiment negatively.
- Surge in Trading Volume: On Monday, trading volume surged to 39.9 million shares, approximately 163% above the three-month average of 15.2 million shares, indicating strong investor reaction to the trial update despite the stock's 9.03% decline.
- Stock Performance: Boston Scientific closed at $62.92, reflecting a 38% drop over the past year, with a forward P/E ratio of 18, suggesting that the stock may be reasonably priced after significant volatility in its performance.
- Market Context: The decline in Boston Scientific's stock aligns with broader pressures in the medical device sector, as peers Medtronic and Stryker also experienced losses, while the S&P 500 and Nasdaq indices fell by 0.39% and 0.73%, respectively.
See More
Boston Scientific's WatchmanFLX Trial Results Lead to Stock Decline
- Trial Overview: Boston Scientific's WatchmanFLX left atrial appendage closure device trial met primary and secondary endpoints in non-valvular atrial fibrillation patients, yet the stock fell 9% on Monday, indicating a negative market reaction.
- Primary Endpoint Comparison: The CHAMPION-AF study revealed that the occurrence of stroke, cardiovascular or unexplained death, and systemic embolism was non-inferior between Watchman and oral anticoagulants, with rates of 5.7% versus 4.8%, suggesting comparable efficacy.
- Safety Analysis: The primary safety endpoint showed that non-procedural major and clinically relevant non-major bleeding rates were significantly lower in the Watchman cohort at 10.9% compared to 19% in the anticoagulant group, highlighting its safety advantage.
- Investor Confidence: Despite a slightly higher ischemic stroke rate in Watchman patients (3.2% vs. 2%), analysts remain optimistic, believing these results will support an increase in WATCHMAN procedure volumes.
See More
US Stock Market Declines Amid Rising Oil Prices
- Oil Price Surge Impacts Markets: The S&P 500 Index fell by 0.75%, the Dow Jones Industrial Average by 0.21%, and the Nasdaq 100 by 1.18% as the market reacts to the first oil settlement exceeding $100 since 2022, highlighting concerns over rising energy costs amid ongoing supply chain risks.
- Uncertain Fed Policy Outlook: Federal Reserve Chair Jerome Powell noted that while the central bank is monitoring the surge in energy prices, its tools to address supply-side shocks are limited, with markets pricing in only a 3% chance of a 25 bp rate hike at the April meeting, indicating investor uncertainty about future monetary policy.
- Escalating Middle East Tensions: US and Israeli forces continue military operations in Iran, with the Pentagon preparing for weeks of ground operations as approximately 3,500 sailors and Marines arrive in the region, potentially exacerbating global energy supply issues.
- Positive Bond Market Reaction: The 10-year Treasury yield fell to 4.330% as speculation grows that the ongoing conflict in the Middle East may lead to fuel shortages, offsetting inflation fears and supporting Treasury prices amid declining inflation expectations.
See More
Boston Scientific Schedules Q1 2026 Earnings Call
- Earnings Call Announcement: Boston Scientific Corporation will host a conference call on April 22, 2026, at 8:00 a.m. ET to discuss its financial results for Q1 2026, providing key business highlights and financial data.
- Executive Leadership: The call will be led by Chairman and CEO Mike Mahoney alongside Executive VP and CFO Jon Monson, ensuring that investors receive insights directly from top management regarding the company's financial performance.
- Pre-Call Financial Release: The company plans to issue a news release announcing its Q1 financial results prior to the call, aiming to provide timely information that helps investors understand the company's financial health and future outlook.
- Live Webcast and Replay: The event will be accessible via a live webcast, with a replay available on Boston Scientific's investor website, ensuring that investors who cannot attend in real-time can still access important information.
See More
Mixed Close for US Stocks as Nasdaq Hits 7.75-Month Low Amid Middle East Tensions
- Divergent Market Performance: On Monday, the S&P 500 index fell by 0.39%, while the Nasdaq 100 hit a 7.75-month low, indicating market concerns over the Middle East situation, particularly exacerbated by a sell-off in chip stocks, which negatively impacted investor confidence.
- Declining Bond Yields: The 10-year T-note yield dropped by 8 basis points to 4.34%, reflecting market fears that the ongoing war in the Middle East could lead to fuel shortages, potentially suppressing expectations for Fed rate hikes and highlighting economic growth uncertainties.
- Rising Crude Oil Prices: Crude oil prices surged over 3% to a three-week high due to Iranian attacks on the Strait of Hormuz, indicating severe threats to global energy supply chains, which could lead to soaring prices in the future and impact the global economy.
- Weak Manufacturing Activity: The Dallas Fed manufacturing activity survey fell to -0.2, below the expected 2.0, reflecting signs of economic slowdown that could influence corporate investment decisions and future economic growth.
See More
Boston Scientific Shares Drop 9.02% Amid Trial Update
- Significant Stock Decline: Boston Scientific (BSX) closed at $62.92 on Monday, down 9.03%, reflecting investor concerns over new clinical trial information regarding its heart implant, which has weakened market confidence in the company's future growth prospects.
- Surge in Trading Volume: The trading volume reached 39.9 million shares, approximately 163% above the three-month average of 15.2 million shares, indicating heightened market attention to the company's news, which may lead to increased short-term price volatility.
- Clinical Trial Update: Boston Scientific announced that its CHAMPION-AF trial met all safety and efficacy endpoints for the Watchman FLX heart implant; however, analysts expressed disappointment, suggesting that growth potential may not accelerate as anticipated.
- Investor Sentiment Analysis: While analysts maintained outperform ratings on Boston Scientific, the stock has dropped 38% over the past year, and with a current P/E ratio of just 18 times forward earnings, investors should view the company's future growth potential rationally and avoid overreacting to a single trial outcome.
See More
Boston Scientific Shares Drop 9.03% Amid Trial Update
- Clinical Trial Update: Boston Scientific announced that its CHAMPION-AF trial for the Watchman heart implant met all safety and efficacy endpoints, yet analysts expressed disappointment, suggesting that growth may not accelerate as anticipated, which could impact investor sentiment negatively.
- Surge in Trading Volume: On Monday, trading volume surged to 39.9 million shares, approximately 163% above the three-month average of 15.2 million shares, indicating strong investor reaction to the trial update despite the stock's 9.03% decline.
- Stock Performance: Boston Scientific closed at $62.92, reflecting a 38% drop over the past year, with a forward P/E ratio of 18, suggesting that the stock may be reasonably priced after significant volatility in its performance.
- Market Context: The decline in Boston Scientific's stock aligns with broader pressures in the medical device sector, as peers Medtronic and Stryker also experienced losses, while the S&P 500 and Nasdaq indices fell by 0.39% and 0.73%, respectively.
See More
Boston Scientific's WatchmanFLX Trial Results Lead to Stock Decline
- Trial Overview: Boston Scientific's WatchmanFLX left atrial appendage closure device trial met primary and secondary endpoints in non-valvular atrial fibrillation patients, yet the stock fell 9% on Monday, indicating a negative market reaction.
- Primary Endpoint Comparison: The CHAMPION-AF study revealed that the occurrence of stroke, cardiovascular or unexplained death, and systemic embolism was non-inferior between Watchman and oral anticoagulants, with rates of 5.7% versus 4.8%, suggesting comparable efficacy.
- Safety Analysis: The primary safety endpoint showed that non-procedural major and clinically relevant non-major bleeding rates were significantly lower in the Watchman cohort at 10.9% compared to 19% in the anticoagulant group, highlighting its safety advantage.
- Investor Confidence: Despite a slightly higher ischemic stroke rate in Watchman patients (3.2% vs. 2%), analysts remain optimistic, believing these results will support an increase in WATCHMAN procedure volumes.
See More
US Stock Market Declines Amid Rising Oil Prices
- Oil Price Surge Impacts Markets: The S&P 500 Index fell by 0.75%, the Dow Jones Industrial Average by 0.21%, and the Nasdaq 100 by 1.18% as the market reacts to the first oil settlement exceeding $100 since 2022, highlighting concerns over rising energy costs amid ongoing supply chain risks.
- Uncertain Fed Policy Outlook: Federal Reserve Chair Jerome Powell noted that while the central bank is monitoring the surge in energy prices, its tools to address supply-side shocks are limited, with markets pricing in only a 3% chance of a 25 bp rate hike at the April meeting, indicating investor uncertainty about future monetary policy.
- Escalating Middle East Tensions: US and Israeli forces continue military operations in Iran, with the Pentagon preparing for weeks of ground operations as approximately 3,500 sailors and Marines arrive in the region, potentially exacerbating global energy supply issues.
- Positive Bond Market Reaction: The 10-year Treasury yield fell to 4.330% as speculation grows that the ongoing conflict in the Middle East may lead to fuel shortages, offsetting inflation fears and supporting Treasury prices amid declining inflation expectations.
See More
